ClinicalTrials.gg
Active, not recruitingNCT06402838Updated Nov 6, 2026

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

A Phase 2 interventional study of RO7269162 and Placebo in Alzheimer's Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 45 sites in 9 countries. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 6, 20261 site added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Enrollment
19th of 40
256 · median 247
Started
2024
the only one that year
Phase 2
12 of 40
1 open now
Registered
34th of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 19th largest by enrollment, is the only one that started in 2024, is one of 12 in phase 2, and was the 34th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18 to 35 kg/m\^2 inclusive at screening
  • Participants must be either cognitively unimpaired or with a diagnosis of MCI due to AD, according to the National Institute on Aging - Alzheimer's Association (NIA - AA) research framework
  • Clinical Dementia Rating-Global Score (CDR-GS) of 0 or 0.5
  • Positive amyloid PET scan based on a cut-off of ≥24 CL units
  • Availability of a person (referred as a "study partner" throughout the protocol) who: (a) has frequent and sufficient contact (e.g., minimum twice a week in-person, via telephone, video calls, by e-mail or other electronic means) with the participant, and is willing and able to provide accurate information regarding the participant's cognitive and functional abilities, signs the necessary ICF(s), and has sufficient cognitive capacity to accurately report on the participant's cognitive and functional abilities; (b) is in sufficient good general health to have a high likelihood of maintaining the same level of interaction with the participant and participation in study procedures throughout the duration of the study; and (c) is fluent in the language of the tests used at the study site. Please note that the study partner does not need to be a family member. Every effort should be made to keep the same study partner throughout the study
  • In case of treatment with symptomatic AD medications, dosing regimen must be stable for at least eight weeks prior to baseline

Exclusion criteria

Exclusion Criteria:

  • Any medical history or evidence of a condition other than AD that may affect cognition
  • History or presence of significant cardiovascular conditions and/or significant hematological disease
  • History or presence of chronic kidney disease and/or impaired hepatic function
  • Uncontrolled/poorly controlled diabetes
  • History of or active inflammatory bowel disease
  • Have received any passive or active immunotherapy (immunoglobulin) or other long-acting biologic agent that is under evaluation or approved to prevent or postpone cognitive decline administered within 1 year prior to baseline, and/or any other treatment within five half-lives or 16 weeks prior to screening, whichever is longer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    RO7269162

    Participants will receive daily doses of RO7269162 for up to 72 weeks.

    Drug: RO7269162

  • Placebo comparator
    Placebo

    Participants will receive daily doses of placebo for up to 72 weeks.

    Drug: Placebo

Interventions

  • DrugRO7269162

    Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.

  • DrugPlacebo

    Participants will receive daily doses of placebo for up to 72 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: up to week 72

  2. Change from baseline in brain amyloid load, as measured by amyloid positron emission tomography ( PET) scan

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Change from baseline in Aβ37 in cerebrospinal fluid (CSF)

    Time frame: Baseline to Week 72

  2. Change from baseline in Aβ38 in CSF

    Time frame: Baseline to Week 72

  3. Change from baseline in Aβ40 in CSF

    Time frame: Baseline to Week 72

  4. Change from baseline in Aβ42 in CSF

    Time frame: Baseline to Week 72

  5. Change from baseline in Aβ40 in plasma

    Time frame: Baseline to Week 72

  6. Change from baseline in Aβ42 in plasma

    Time frame: Baseline to Week 72

  7. Plasma concentrations of RO7269162

    Time frame: Baseline to Week 72

  8. CSF concentrations of RO7269162

    Time frame: Baseline to Week 72

Other outcomes

  1. Change from baseline in p-tau 217 in plasma

    Time frame: Baseline to Week 72

07

Study locations

45 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2026, 30 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 30 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 7, 2024
StartActual
May 2, 2024
Primary completionEst.
Nov 19, 2026
CompletionEst.
Nov 19, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed
Show site
  • Gachon University Gil Medical Center · Incheon, South Korea
Show 2 removed
  • ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic · Berlin, Germany
  • Inha University Hospital · Incheon, South Korea
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 2 sites removed
    Show site
    • Gachon University Gil Medical Center · Incheon, South Korea
    Show 2 removed
    • ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic · Berlin, Germany
    • Inha University Hospital · Incheon, South Korea
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06402838
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 7, 2024
Start date
May 2, 2024
Primary completion
Nov 19, 2026 (estimated)
Completion
Nov 19, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion